Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin Reports First Quarter 2026 Financial and Operating Results
04:05pm, Monday, 04'th May 2026
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Tuesday, 28'th Apr 2026
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Completes Acquisition of Amicus Therapeutics
08:44am, Monday, 27'th Apr 2026
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects
Pre-Market Stock Futures: The futures are trading lower as we get set to start a new trading week, and after last week's string of record highs, it may be tough to duplicate the stellar performance th
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
07:30am, Monday, 27'th Apr 2026
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
11:13am, Saturday, 25'th Apr 2026
Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.
BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Asset Management One Co. Ltd.
03:56am, Saturday, 25'th Apr 2026
Asset Management One Co. Ltd. reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 92.5% in the undefined quarter, according to the company in its most recent 13F filing with the Sec
BioMarin Announces Board Leadership Transition
04:23pm, Tuesday, 21'st Apr 2026
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
12:54pm, Wednesday, 15'th Apr 2026
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
12:31pm, Wednesday, 25'th Mar 2026
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin stops mid-stage trials of bone disorder treatment
09:40am, Monday, 16'th Mar 2026
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, buildin
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN
03:45am, Thursday, 12'th Mar 2026
Dimensional Fund Advisors LP grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 42.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. T
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:22pm, Wednesday, 11'th Mar 2026
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
